Displaying drugs 10201 - 10225 of 12422 in total
Managlinat dialanetil
CS-917 is a novel inhibitor of fructose 1,6-bisphphosphatase (FBPase) which is one of the rate-limiting enzymes of gluconeogenesis.
Investigational
Matched Description: … enzymes of gluconeogenesis. ... CS-917 is a novel inhibitor of fructose 1,6-bisphphosphatase (FBPase) which is one of the rate-limiting …
Rozrolimupab
Rozrolimupab is a recombinant polyclonal antibody consisting of 25 different anti-Rhesus D (RhD) antibodies to replace existing anti-RhD hyperimmune immunoglobulins for the treatment of Idiopathic Thrombocytopenic Purpura (ITP) and the prevention of Hemolytic Disease of Newborns (HDN).
Investigational
Matched Description: … Purpura (ITP) and the prevention of Hemolytic Disease of Newborns (HDN). ... Rozrolimupab is a recombinant polyclonal antibody consisting of 25 different anti-Rhesus D (RhD) antibodies ... to replace existing anti-RhD hyperimmune immunoglobulins for the treatment of Idiopathic Thrombocytopenic …
Amuvatinib
Amuvatinib has been used in trials studying the treatment of Solid Tumors and Small Cell Lung Carcinoma. Amuvatinib is an oral, selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of c-KIT, PDGFR and FLT3. Amuvatinib also suppresses Rad51 protein, a critical component of double-stranded DNA...
Investigational
Matched Description: … Amuvatinib has been used in trials studying the treatment of Solid Tumors and Small Cell Lung Carcinoma ... selective multi-targeted tyrosine kinase inhibitor that suppresses c-MET, c-RET and the mutant forms of ... Amuvatinib also suppresses Rad51 protein, a critical component of double-stranded DNA repair in cancer …
G4544
G4544 is an oral gallium compound that enables oral absorption of the active ingredient contained in Ganite™ (gallium nitrate injection). It targets bone tissue and is actively incorporated into bone mineral at sites where bone is metabolically active.
Investigational
Matched Description: … G4544 is an oral gallium compound that enables oral absorption of the active ingredient contained in …
Amolimogene
Amolimogene is an investigational therapeutic designed to specifically augment the body's defensive response to human papillomavirus (HPV). Amolimogene was biologically engineered as a targeted therapy for the treatment of cervical dysplasia.
Investigational
Matched Description: … Amolimogene was biologically engineered as a targeted therapy for the treatment of cervical dysplasia …
PH-284
PH-284 belongs to a new family of new chemical entities called vomeropherins. Vomeropherins are self-administered by the patient with a metered nasal spray, or nasal aerosol device so that they can bind to peripheral chemosensory receptors in the nasal passages. This binding produces neural impulses that are transmitted by specific...
Investigational
Matched Description: … PH-284 is under investigation by Pherin and Organon for the treatment of anorexia nervosa, and loss of ... PH-284 belongs to a new family of new chemical entities called vomeropherins. …
AX200
AX200, which has been developed for the treatment of stroke, is the most advanced drug candidate and is halfway through the process of gaining clinical approval. The expression of the endogenous AX200 protein in the brain is increased after brain damage. Thus, if this drug administered in the acute phase...
Investigational
Matched Description: … stroke, while stimulating simultaneously the regeneration of nervous tissue through the induction of ... is halfway through the process of gaining clinical approval. ... neuro- and arteriogenesis and supporting the reorganisation of the nervous system. …
TAFA-93
TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical development. mTOR inhibitors are currently used in the prevention of organ rejection in transplantation, the treatment of autoimmune and oncological diseases, and as a component of coated stents for the treatment of coronary...
Investigational
Matched Description: … of coronary artery disease. ... , the treatment of autoimmune and oncological diseases, and as a component of coated stents for the treatment ... TAFA93 is a novel prodrug of the mTOR inhibitor rapamycin which has successfully completed Phase 1 clinical …
ICA-105665
ICA-105665 is a novel small molecule compound for the treatment of epilepsy. It is a novel opener of the KCNQ ion channel which in preclinical studies has demonstrated a broad spectrum of activity in models of epilepsy. In addition, ICA-105665 has also demonstrated activity in certain models of neuropathic pain.
Investigational
Matched Description: … of activity in models of epilepsy. ... ICA-105665 is a novel small molecule compound for the treatment of epilepsy. ... In addition, ICA-105665 has also demonstrated activity in certain models of neuropathic pain. …
PRO 2000
PRO 2000 is an investigational medicine that is not yet approved by the FDA for use outside of clinical trials. It is being studied for the prevention of HIV infection and other sexually transmitted diseases. This medicine does not cure HIV infection or AIDS and is being studied to reduce...
Investigational
Matched Description: … PRO 2000 is an investigational medicine that is not yet approved by the FDA for use outside of clinical ... It is being studied for the prevention of HIV infection and other sexually transmitted diseases. ... This medicine does not cure HIV infection or AIDS and is being studied to reduce the risk of passing …
SC12267
SC12267 is a novel, small molecule agent from the class of DMARDs (disease modifying anti-rheumatic drug) for the therapy of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. Through highly selective inhibition of pyrimidine biosynthesis, it controls the growth of rapidly proliferating cells, especially of lymphocytes, which are important...
Investigational
Matched Description: … Through highly selective inhibition of pyrimidine biosynthesis, it controls the growth of rapidly proliferating ... cells, especially of lymphocytes, which are important for the immune response. ... ) for the therapy of autoimmune diseases such as rheumatoid arthritis or multiple sclerosis. …
Platelet Lysate
Platelet lysate is an acellular compound composed of platelet proteins while also being void of cellular debris, thus making the lysate rich with growth factors. It is extracted through lysis of the plasma membrane of platelets. Because white cell antigens are low in prepared lysate, there is a minimized likelihood...
Investigational
Matched Description: … [A220188] It is extracted through lysis of the plasma membrane of platelets. ... Platelet lysate is an acellular compound composed of platelet proteins while also being void of cellular ... Because white cell antigens are low in prepared lysate, there is a minimized likelihood of immune responses …
NP-50301
NP-50301 is an ophthalmic therapeutic eye drop treating post-menopausal Dry Eye Syndrome (DES). It is being developed by Nascent Pharmaceuticals. It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S. The majority of sufferers of DES are...
Investigational
Matched Description: … It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over ... The majority of sufferers of DES are postmenopausal women; and clinical research around the world has ... suggested the benefits of both topical and systemic estrogen therapy in the treatment of DES in this …
Maplirpacept
Maplirpacept is a recombinant fusion protein consisting of the CD47-binding domain of human signal regulatory protein alpha (SIRPa) linked to the IgG4 Fc region of human IgG.
Investigational
Matched Description: … Maplirpacept is a recombinant fusion protein consisting of the CD47-binding domain of human signal regulatory ... protein alpha (SIRPa) linked to the IgG4 Fc region of human IgG. …
BMS-919373
BMS-919373 is under investigation in clinical trial NCT02153437 (Study of the Effects of BMS-919373 on the Electrical Activity of the Heart Using Pacemakers).
Investigational
Matched Description: … BMS-919373 is under investigation in clinical trial NCT02153437 (Study of the Effects of BMS-919373 on ... the Electrical Activity of the Heart Using Pacemakers). …
Aceprometazine
Aceprometazine is a is a drug with neuroleptic and anti-histamine properties. Although not widely prescribed, it is used in combination with meprobamate for the treatment of sleep disorders in France under the trade name Mepronizine.
Experimental
Matched Description: … Although not widely prescribed, it is used in combination with meprobamate for the treatment of sleep …
Go-6976
An inhibitor of calcium-dependent isoforms of protein kinase C.[A253002,A253007]
Investigational
Matched Description: … An inhibitor of calcium-dependent isoforms of protein kinase C.[A253002,A253007] …
Carphenazine
Carphenazine is an antipsychotic drug, used in hospitalized patients in the management of chronic schizophrenic psychoses.
Withdrawn
Matched Description: … Carphenazine is an antipsychotic drug, used in hospitalized patients in the management of chronic schizophrenic …
Bifeprunox
Bifeprunox is a novel atypical antipsychotic agent which, along with SLV313, aripiprazole and SSR-181507 combines minimal D2 receptor agonism with 5-HT receptor agonism.
Investigational
Lucanthone
One of the schistosomicides, it has been replaced largely by hycanthone and more recently praziquantel. (From Martindale The Extrapharmacopoeia, 30th ed., p46). It is currently being tested as a radiation sensitizer.
Investigational
Matched Description: … One of the schistosomicides, it has been replaced largely by hycanthone and more recently praziquantel …
Daclizumab
Humanized IgG1 Mab that binds to the human interleukin-2 receptor (anti-Tac or anti-CD25). Daclizumab is a composite of human (90%) and murine (10%) antibody sequences. The human sequences were derived from the constant domains of human IgG1 and the variable framework regions of the Eu myeloma antibody. The murine sequences...
Investigational
Withdrawn
Matched Description: … of the Eu myeloma antibody. ... Regardless of the withdrawal of Zenapax, Biogen and Abbvie's Zinbryta (daclizumab), as indicated for ... the treatment of adult patients with relapsing forms of multiple sclerosis, was approved for use by the …
Etrolizumab
Inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease, is typified by a chronic gastrointestinal inflammatory microenvironment, driven in part by the excessive infiltration and retention of intestinal-homing lymphocytes.[A244564, A244569, A244579, A244584] A recent class of drugs designed to impair lymphocyte homing, so-called "anti-trafficking agents" (ATAs), have shown some...
Investigational
Matched Description: … in undesirable blockade of lymphocyte CNS trafficking and reported cases of progressive multifocal leukoencephalopathy ... [A244574] In the case of [natalizumab], which targets the α4 integrin subunit, this has also resulted ... gastrointestinal inflammatory microenvironment, driven in part by the excessive infiltration and retention of …
NS-2359
NS2359 is a triple monoamine re-uptake inhibitor with a new, unique drug profile expected to yield important benefits compared to existing treatments of depression. Enhancing the function of the three neurotransmitters serotonin, noradrenalin and dopamine, NS2359 has a desired "triple-mode-of-action". This mode of action is expected to produce an optimal...
Investigational
Matched Description: … of an earlier onset of action compared to antidepressants already on the market. ... a desired "triple-mode-of-action". ... with a new, unique drug profile expected to yield important benefits compared to existing treatments of …
Plozalizumab
Plozalizumab has been investigated for the treatment of Atherosclerosis. Plozalizumab, a novel humanized monoclonal antibody, specifically targets CCR2 chemokine receptors found on the surface of certain white blood cells including macrophages and monocytes. Preclinical studies suggest that CCR2 plays an important role in the trafficking of monocytes and macrophages to...
Investigational
Matched Description: … of atherosclerosis. ... to sites of inflammation. ... Plozalizumab has been investigated for the treatment of Atherosclerosis. …
Ciraparantag
Ciraparantag is under investigation in clinical trial NCT01826266 (Effects of a Double-Blind, Single Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban).
Investigational
Matched Description: … Dose of PER977 Administered Alone, and Following a Single Dose of Edoxaban). ... Ciraparantag is under investigation in clinical trial NCT01826266 (Effects of a Double-Blind, Single …
Displaying drugs 10201 - 10225 of 12422 in total